home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Research may lead to better schizophrenia drugs

 
  July, 6 2003 20:29
your information resource in human molecular genetics
 
     
The study, reported this week in the early online edition of the Proceedings of the National Academy of Sciences, may lead to the first genetically targeted drugs for the disease, which affects 1 percent of the population worldwide.

Nobel laureate Susumu Tonegawa, director of the Picower Center for Learning and Memory at MIT and a Howard Hughes Medical Institute investigator, found that genetically engineered mice lacking the brain protein calcineurin exhibit a number of behavioral abnormalities shared by schizophrenic patients.

In a related study with researchers at Rockefeller University in New York, MIT scientists show that variation in a human calcineurin gene also is associated with schizophrenia. Calcineurin--part of a biochemical pathway in the brain linked to receptors for two brain chemicals, NMDA and dopamine--plays a significant role in the central nervous system.

This is the first study that uses animals who demonstrate an array of symptoms observed in schizophrenic patients to identify specific genes that predispose people to the disease.

MICE AND MEMORY

Tonegawa creates tools to explore the genetic underpinnings of the molecular mechanism for memory. Genetically engineered mice who are missing the brain enzyme calcineurin were previously shown to have an impairment in short-term, day-to-day memory formation, known as working memory. This kind of memory also is impaired in schizophrenia patients.

Further testing of these mice by Picower Center research scientist Tsuyoshi Miyakawa revealed that they also have attention deficits, aberrant social behavior and several other abnormalities characteristic of schizophrenia.

Picower Center research scientist David Gerber then collaborated with Rockefellerís Maria Karayiorgou to examine calcineurin genes in DNA samples from schizophrenic patients and their immediate relatives. The researchers found an association between a particular calcineurin gene and schizophrenia.

"This is an intriguing series of findings," Tonegawa said. "The combination of evidence from the genetically altered mice, together with the human gene studies, create a strong argument to link calcineurin with schizophrenia."

A SEARCH FOR DRUGS

Alterations in multiple genes are believed to predispose people to schizophrenia. Tonegawa suspects that many of these genes may turn out to be components of the calcineurin pathway or to directly interact with the calcineurin pathway.

"Once we better understand exactly which genes are involved, we will know how proteins are affected, and we can set up a test to screen large numbers of compounds to identify ones that have desired effects on the activity of these proteins," Tonegawa said. "This can potentially lead to the discovery of new kinds of drugs for psychiatric conditions such as schizophrenia."

In addition to Gerber, Miyakawa, Karayiorgou and Tonegawa, co-authors include Joseph A. Gogos of Columbia University, and Diana Hall and Sandra Demars of Rockefeller University. Authors on the mouse study include research specialist Lorene M. Leiter and Hongkui Zeng of MIT, and Raul R. Gainetdinov, Tatyana D. Sotnikova and Marc G. Caron of Duke University.

The study on the human genes associated with schizophrenia susceptibility was funded by the Picower Foundation, the National Institutes of Health, the Howard Hughes Medical Institute, the Otsuka Maryland Research Institute, the McKnight Endowment Fund for Neuroscience, the EJLB Foundation and the New York City Council Speakerís Fund.

The study on the genetically altered schizophrenic mice was funded by the Picower Foundation, the National Institutes of Health, the Howard Hughes Medical Institute, RIKEN and NARSAD.

Contact:
Deborah Halber
MIT News Office
(617) 258-9276
dhalber@mit.edu


Message posted by: Frank S. Zollmann

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

ĎPro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.